Kaoru Ri
YOU?
Author Swipe
View article: Retinal and Choriocapillaris Thickness Changes in Spontaneously Diabetic Macaques
Retinal and Choriocapillaris Thickness Changes in Spontaneously Diabetic Macaques Open
Consistent with humans, early diabetes in cynomolgus macaques results in notable alterations in retinal thickness, particularly affecting the nasal inner retina. The observed increase in choriocapillaris thickness in both diabetic macaques…
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Constitutively active mutant EGFR is one of the major oncogenic drivers in non–small cell lung cancer (NSCLC). Targeted therapy using EGFR tyrosine kinase inhibitor (TKI) is a first-line option in patients that have metastatic or recurring…
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 4A shows the expression of MET and P-MET in naive and treated tumors. Supplement Figure 4B shows the sequencing result of EGFR exon 20 flanking C797 in naive and treated tumors.
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Selected characteristics of the PDX models used in the study. Data were extracted from the database of The Jackson Laboratory
View article: Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Constitutively active mutant EGFR is one of the major oncogenic drivers in non–small cell lung cancer (NSCLC). Targeted therapy using EGFR tyrosine kinase inhibitor (TKI) is a first-line option in patients that have metastatic or recurring…
View article: Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Data from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Constitutively active mutant EGFR is one of the major oncogenic drivers in non–small cell lung cancer (NSCLC). Targeted therapy using EGFR tyrosine kinase inhibitor (TKI) is a first-line option in patients that have metastatic or recurring…
View article: Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Anti-HDGF antibody enhances the efficacy of EGFR-targeted therapy. Mice with established PDXs of NSCLC tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody. A and B, Spider plot of…
View article: Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
HDGF expression in naïve and osimertinib-treated PDX tumors. Formalin-fixed, paraffin-embedded sections of TM00219 PDX tumors were stained with mouse anti–HDGF antibody T221. Representative fields (10×) of staining in naïve, osimertinib-tr…
View article: Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 5 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
HDGF expression in naïve and osimertinib-treated PDX tumors. Formalin-fixed, paraffin-embedded sections of TM00219 PDX tumors were stained with mouse anti–HDGF antibody T221. Representative fields (10×) of staining in naïve, osimertinib-tr…
View article: Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Dynamics of EGFR signaling during the early stage of osimertinib treatment. Mice bearing TM00219 tumors were treated with osimertinib (10 mg/kg per os, every 24 hours) for up to 72 hours. Duplicate tumor samples were serially collected at …
View article: Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 3 shows the Effect of anti-HDGF antibody H3 on post-progression tumor.
View article: Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 3 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Dynamics of EGFR signaling during the early stage of osimertinib treatment. Mice bearing TM00219 tumors were treated with osimertinib (10 mg/kg per os, every 24 hours) for up to 72 hours. Duplicate tumor samples were serially collected at …
View article: Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 4 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Effect of anti-HDGF antibody on EGFR signaling in osimertinib-treated TM00219 PDX tumor. Mice with established TM00219 PDX tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody H3. …
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Characteristics of HDGF binding by humanized anti-HDGF antibody H3. A, Binding of native HDGF by anti-HDGF antibody H3. Recombinant H3 was immobilized on protein G agarose beads and used to capture HDGF in HEK293 lysate. Lane 1, H3 loaded-…
View article: Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 2 shows the Effect of anti-HDGF antibody H3 on treatment naive tumor.
View article: Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Table 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Selected characteristics of the PDX models used in the study. Data were extracted from the database of The Jackson Laboratory
View article: Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Supplement Figure 1 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Supplement Figure 1 shows the incomplete response of Hcc827 tumor to erlotinib treatment.
View article: Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts Open
Anti-HDGF antibody enhances the efficacy of EGFR-targeted therapy. Mice with established PDXs of NSCLC tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody. A and B, Spider plot of…